Investasi
Fitur
BiayaKeamanan
Akademi
Lainnya
Pluang+

Bandingkan Harga & Kinerja Fimperkasa Utama Tbk. (FIMP) vs Organon Pharma Indonesia Tbk. (SCPI)

Fimperkasa Utama Tbk.Trading
Organon Pharma Indonesia Tbk.Trading

Kinerja harga (24 Jam Terakhir)

Statistik utama

Perbedaan Fimperkasa Utama Tbk. dan Organon Pharma Indonesia Tbk.: Fimperkasa Utama Tbk. diperdagangkan di Rp69 (kapitalisasi pasar 27,6 M), sedangkan Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M). Perbedaan utamanya: Organon Pharma Indonesia Tbk. jauh lebih besar — sekitar 3,8× kapitalisasi pasar Fimperkasa Utama Tbk.. Mana yang lebih baik tergantung tujuan investasimu.

FIMPSCPI
Kapitalisasi Pasar
27,6 M104,4 M

Perbandingan imbal hasil

Imbal hasil berjalan pada periode standar

Berita terkini

Berita terbaru kedua aset

FIMP
Lihat detail
SCPI
Lihat detail

Tentang Fimperkasa Utama Tbk.

PT Fimperkasa Utama Tbk (the "Company”) established in Indonesia based on Notarial Deed No. 41 of Adam Kasdarmadji, S.H., on February 08, 1993. The Company commenced its commercial operations in 1996. The majority shareholder of the Company is Mohamad Mulky Thalib,

Selengkapnya di halaman FIMP

Tentang Organon Pharma Indonesia Tbk.

PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.

Selengkapnya di halaman SCPI